Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
February 28 2023 - 7:30AM
Agenus (Nasdaq: AGEN), an immuno-oncology company with a pipeline
of immunological agents targeting cancer and infectious disease,
today announced the Company will release its fourth quarter and
full year 2022 financial results before the market opens on
Tuesday, March 14, 2023. Agenus executives will host a conference
call and webcast at 8:30 a.m. ET that morning to discuss the
results and to provide a corporate update.
Conference CallDial-in numbers: (646) 307-1963
(US-NY) or (800) 715-9871 (US & CA)Conference ID: 2699739
WebcastA live webcast and replay of the
conference call will be accessible from the Events &
Presentations page of the Company’s website at
https://investor.agenusbio.com/events-and-presentations and via
https://edge.media-server.com/mmc/p/p9dyor73.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to our technologies, therapeutic candidates,
and capabilities, for instance, statements regarding therapeutic
benefit and efficacy, mechanism of action, potency, durability, and
safety and tolerability profile of our therapeutic candidates, both
alone and in combination with each other and/or other agents;
statements regarding future plans, including research, clinical,
regulatory, and commercialization plans; and any other statements
containing the words "may," "believes," "expects," "anticipates,"
"hopes," "intends," "plans," "will" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission and available on our website:
www.agenusbio.com. Agenus cautions investors not to place
considerable reliance on the forward-looking statements contained
in this release. These statements speak only as of the date of this
press release, and Agenus undertakes no obligation to update or
revise the statements, other than to the extent required by law.
All forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
ContactAgenus Inc.Zack ArmenHead of Investor
Relations917-362-1370zack.armen@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2024 to Jun 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2023 to Jun 2024